Global Markets
S&P 500 — US Large Cap Index
NASDAQ 100 — Tech Growth Index
Dow Jones — Industrial Average
FTSE 100 — UK Blue Chips
Euro Stoxx 50 — Eurozone Leaders
DAX 40 — German Equities
CAC 40 — French Market Index
Nikkei 225 — Japan Benchmark
Hang Seng — Hong Kong Index
Shanghai Composite — China Mainland
ASX 200 — Australian Market
TSX Composite — Canada Index
Nifty 50 — India Large Cap
STI Index — Singapore Market
KOSPI — South Korea Index
Bovespa — Brazil Equities
JSE Top 40 — South Africa Index
IPC Index — Mexico Market
S&P 500 — US Large Cap Index
NASDAQ 100 — Tech Growth Index
Dow Jones — Industrial Average
FTSE 100 — UK Blue Chips
Euro Stoxx 50 — Eurozone Leaders
DAX 40 — German Equities
CAC 40 — French Market Index
Nikkei 225 — Japan Benchmark
Hang Seng — Hong Kong Index
Shanghai Composite — China Mainland
ASX 200 — Australian Market
TSX Composite — Canada Index
Nifty 50 — India Large Cap
STI Index — Singapore Market
KOSPI — South Korea Index
Bovespa — Brazil Equities
JSE Top 40 — South Africa Index
IPC Index — Mexico Market
Indices

ASX 200 Up 0.7% at Close

Australia’s ASX 200 rose 59 points, or 0.7%, to end at 8,823 on Monday, building strength from the prior session amid a sharp rise in U.S. stock futures as Washington and Tehran reportedly agreed to halt hostilities and resume peace talks. Sentiment was also lifted by strong growth in China’s industrial profits over the first five months of 2026, highlighting resilience in Australia’s key trading partner. However, caution emerged ahead of China’s June PMI data later this week, both from officials and a private survey. Meanwhile, the Reserve Bank’s June minutes will also be due, with investors wary that the central bank may retain its tightening bias to rein in inflation. Commercial services, consumer non-durables, and healthcare drove the gains. Strong iron ore prices supported BHP Group (1.4%) and Fortescue (2.4%). Ramelius Resources climbed 2.3% after agreeing to sell its Edna May Gold Hub. Neuren Pharmaceuticals surged 36.1% on EU approval for its Rett syndrome drug.

Octalas AI
Octalas Logo

Profit

Everyone's racing to cut costs. We're racing to create profit.

Start Selling through Service

Free for 14 days · No credit card required
Profit Through AI

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also
Close
Back to top button